Thera-SAbDab

TIGATUZUMAB

>   Structural Summary
TherapeuticTigatuzumab
TargetTNFRSF10B
Heavy ChainEVQLVESGGGLVQPGGSLRLSCAASGFTFSSYVMSWVRQAPGKGLEWVATISSGGSYTYYPDSVKGRFTISRDNAKNTLYLQMNSLRAEDTAVYYCARRGDSMITTDYWGQGTLVTVSS
Light ChainDIQMTQSPSSLSASVGDRVTITCKASQDVGTAVAWYQQKPGKAPKLLIYWASTRHTGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYSSYRTFGQGTKVEIK
100% seqID Fv StructureNone
99% seqID Fv StructureNone
95-98% seqID Fv StructureNone
>   Metadata
FormatWhole mAb
IsotypeG1
Highest Clinical Trial (June '19)Phase-II
Estimated Status (June '19)Discontinued
Recorded Developmental Technologyna
INN Year Proposed2007
INN Year Recommended2008
Companies InvolvedDaiichi Sankyo Company, University of Alabama at Birmingham
Conditions Approvedna
Conditions Activena
Conditions DiscontinuedBreast cancer, Colorectal cancer, Liver cancer, Lymphoma, Non-small cell lung cancer, Ovarian cancer, Pancreatic cancer
Notes

SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]

Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]